International Symposium on Hodgkin's Disease. Session 5. Treatment. Current status of clinical trials: Stanford experience, 1962-72.
D001706:Biopsy; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006048:Gold Colloid, Radioactive / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000145:classification / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012008:Recurrence; D013160:Splenic Neoplasms / Q000628:therapy; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D006048:Gold Colloid, Radioactive; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone